2022
Oral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients
John BV, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Dahman B. Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients. Gastroenterology 2021, 162: 645-647.e2. PMID: 34758352, PMCID: PMC8572555, DOI: 10.1053/j.gastro.2021.11.001.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionLiver transplant recipientsTransplant recipientsVaccinationInfectionRecipientsAssociation of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis
John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine 2021, 181: 1306-1314. PMID: 34254978, PMCID: PMC8278308, DOI: 10.1001/jamainternmed.2021.4325.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19-related hospitalizationBNT162b2 mRNAFirst doseCohort studySecond doseMRNA vaccinesClinical trialsControl groupPropensity-matched control groupPhase 3 clinical trialsCOVID-19 mRNA vaccinesAssociation of vaccinationRetrospective cohort studyUS veteran populationAssociation of receiptVeterans Health AdministrationCoronavirus disease 2019COVID-19 hospitalizationMRNA vaccine administrationCOVID-19Vaccine recipientsImmune dysregulationModerna mRNAMedian ageFactors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease
Kanwal F, Hernaez R, Liu Y, Taylor TJ, Rana A, Kramer JR, Naik AD, Smith D, Taddei T, Asch SM. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine 2021, 181: 949-959. PMID: 34028505, PMCID: PMC8145153, DOI: 10.1001/jamainternmed.2021.2051.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAdvanced liver diseaseLiver diseaseLiver transplantationCohort studyMedical recordsOrgan transplantsVeterans Affairs Health Care SystemLower ratesRetrospective cohort studyWait-listed patientsAfrican American patientsComprehensive electronic medical recordsElectronic medical recordsHealth care systemReferral stepsLiver allograftsLiver transplantAdult patientsAlcohol etiologyLow annual incomePatient ageCurative therapyLiver cirrhosisSodium scoreUrsodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.Peer-Reviewed Original ResearchConceptsLiver-related deathPrimary biliary cholangitisUDCA responseHepatic decompensationHepatocellular carcinomaUrsodeoxycholic acidUDCA respondersPortal hypertensionPartial respondersBiliary cholangitisTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityRetrospective cohort studyProportional hazards modelPBC cirrhosisCompensated cirrhosisCohort studyMale patientsClinical benefitUnadjusted ratesCirrhosisReduced mortalityDecompensation
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrialsImpact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal Of Cancer 2020, 124: 407-413. PMID: 33071284, PMCID: PMC7852559, DOI: 10.1038/s41416-020-01116-9.Peer-Reviewed Original ResearchConceptsOverall survivalHepatocellular carcinomaCohort studySorafenib-related toxicityInternational cohort studyMedian overall survivalMulticentre cohort studyLow-dose therapyCommon prognostic factorsSimilar overall incidenceDoses of sorafenibImpact of ageConclusionsClinical outcomesSorafenib 800Sorafenib dosingElderly patientsOlder patientsPrognostic factorsOverall incidenceClinical efficacyLiver functionLarge tumorsMultivariable modelGrade 2PatientsPatterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study
Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re V, Akgün KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLOS Medicine 2020, 17: e1003379. PMID: 32960880, PMCID: PMC7508372, DOI: 10.1371/journal.pmed.1003379.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBlack or African AmericanClinical Laboratory TechniquesCohort StudiesCoronavirus InfectionsCOVID-19COVID-19 TestingEthnicityFemaleHispanic or LatinoHumansMaleMiddle AgedPandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2United StatesVeteransWhite PeopleYoung AdultConceptsCOVID-19 testingRace/ethnicityCohort studyWhite individualsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionCOVID-19Large integrated healthcare systemCoronavirus 2 infectionNationwide cohort studyRetrospective cohort studyCoronavirus disease 2019Site of careIntegrated healthcare systemNon-Hispanic blacksPositive test resultsNon-Hispanic whitesClinical characteristicsMultivariable adjustmentComorbid conditionsMedication historyEthnic minority communitiesDisease 2019
2019
Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial
Verma M, Kosinski AS, Volk ML, Taddei T, Ramchandran K, Bakitas M, Green K, Green L, Navarro V. Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial. Journal Of Palliative Medicine 2019, 22: s-34-s-43. PMID: 31486722, DOI: 10.1089/jpm.2019.0121.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseQuality of lifePalliative careESLD patientsLiver diseaseMulticenter cluster-randomized trialPatients' QOLPatient-caregiver dyadsRoutine outpatient careComparative effectiveness trialHealth care utilizationGoal-concordant careCluster-randomized trialUnit of randomizationPrinciples of PCEligible patientsPC interventionsNew onsetAcute episodeSecondary outcomesSymptom burdenConcordant carePrimary outcomeCare utilizationCaregiver burden
2017
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study
Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal Of Clinical Oncology 2017, 35: jco.2017.73.824. PMID: 28872925, PMCID: PMC5662845, DOI: 10.1200/jco.2017.73.8245.Peer-Reviewed Original ResearchConceptsSorafenib patientsHazard ratioOverall survivalHepatocellular carcinomaPotential confoundersNoninferiority marginEnd-stage liver disease-sodium (MELD-Na) scoreVeterans Health Administration hospitalsHigher Child-TurcottePotential treatment biasReduced pill burdenComorbidity Index scorePrimary end pointFirst-line therapyGastrointestinal adverse effectsDose of sorafenibSignificant OS differenceAdvanced hepatocellular carcinomaLower overall survivalMultivariate logistic regressionMulti-institutional studyChild-TurcotteOS relativePugh scorePurpose Sorafenib
2016
Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old man
Ooka K, Onyiuke I, Zhang X, Taddei TH. Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old man. BMJ Case Reports 2016, 2016: bcr2016216649. PMID: 27591041, PMCID: PMC5020720, DOI: 10.1136/bcr-2016-216649.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAbdominal PainAged, 80 and overCarcinoma, HepatocellularHemochromatosisHepatectomyHumansLiver NeoplasmsMalePhlebotomyConceptsHepatocellular carcinomaHereditary haemochromatosisSolitary liver tumorSigns of recurrenceAbdominal painElevated transaminasesHepatic manifestationLiver diseaseLate presentationSurveillance imagingIron overloadRoutine phlebotomyLiver tumorsMultisystem disorderCarcinomaHaemochromatosisNew complicationsCirrhosisPartial hepatectomyIron metabolismMenHepatomegalyPainComplicationsHaemosiderosis